Japan's health panel has given the green light for health insurance coverage of Amchepry, a Parkinson's treatment developed by Sumitomo Pharma using iPS cells. This approval makes it the world's first commercial medical product derived from this technology, marking a milestone in regenerative medicine.
How iPS cells replace damaged neurons 🧬
Amchepry uses induced pluripotent stem cells to generate new dopaminergic neurons, which are implanted into the patient's brain. These cells replace those damaged by the disease, partially restoring dopamine production. The procedure requires stereotactic surgery and immunosuppressive follow-up to prevent rejection, with results aimed at slowing the progression of motor symptoms.
Parkinson: now with factory spare parts 🔧
Finally, Parkinson's patients will be able to swap out their damaged neurons like changing a phone battery. All that's left is for Sumitomo to include an instruction manual and a two-year warranty. Meanwhile, tremors are reduced, although the cost of health insurance will likely cause other kinds of tremors.